July 22, 2026 (Washington, D.C.) – The Partnership for Safe Medicines released a statement today regarding the tragic death of a patient in New York City one hour after receiving an IV infusion of an untested substance that is allowed to be compounded by 503A compounding pharmacies.

The substance in question, NAD+, is legal to prepare by 503A compounders, but was administered by an individual who did not hold a license to practice in the state of New York.

“The FDA has never evaluated NAD+ for efficacy, safety, or quality,” said Executive Director Shabbir Imber Safdar. “It is not a component of an FDA-approved medicine. Patients taking it are subjecting themselves to a massively dangerous, uncontrolled, human trial. Using the compounding rules to circumvent the FDA approval process risks American patients’ lives and undermines the safety of the entire U.S. drug supply.”

“This is also further proof that allowing an untested substance to be compounded does not drive bad actors out of the industry,” said Safdar, “Only prosecutions and good policy can do that.”

Safdar will deliver PSM’s testimony tomorrow at 4:40pm Eastern at the FDA’s Pharmacy Compounding Advisory Committee during the MOTs-C discussion. (Watch live). You can learn more about the five risks of untested peptides on their website.

For more information, contact PSM at editors@safemedicines.org.